Coronado Biosciences (CNDO -5.9%) says it's signed a clinical trial agreement with the National...

|By:, SA News Editor

Coronado Biosciences (CNDO -5.9%) says it's signed a clinical trial agreement with the National Institute of Allergy and Infectious Diseases to evaluate its experimental Trichuris suis ova, or CNDO-201, for the treatment of ulcerative colitis. The multi-center study will examine the safety and efficacy of TSO treatment in active left-sided ulcerative colitis and its effects on mucosal immune state and microbiota.